{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:49:34Z","timestamp":1793659774170,"version":"4.5.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,23]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Tisagenlecleucel (CTL019) has demonstrated clinical efficacy in relapsed\/refractory B-cell ALL and CLL. The cellular kinetic profile of tisagenlecleucel was consistent across the 2 diseases, with higher exposure in responding vs nonresponding patients.<\/jats:p>","DOI":"10.1182\/blood-2017-06-786129","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T01:10:49Z","timestamp":1506042649000},"page":"2317-2325","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":337,"title":["Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"130","author":[{"given":"Karen Thudium","family":"Mueller","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA; and"},{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Frey","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Wood","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Han","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Waldron","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Awasthi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Joseph","family":"Melenhorst","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA; and"},{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Lacey","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111903342328100_B1","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"2","key":"2019111903342328100_B2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.12216","article-title":"CD3\u03b6-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy","volume":"175","author":"Bridgeman","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2019111903342328100_B3","author":"Long"},{"issue":"7","key":"2019111903342328100_B4","doi-asserted-by":"crossref","first-page":"e69677","DOI":"10.1371\/journal.pone.0069677","article-title":"4-1BB signaling activates the t cell factor 1 effector\/\u03b2-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K\/AKT activation to promote the proliferation of CD8+ T Cells","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"issue":"23","key":"2019111903342328100_B5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019) [abstract]","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2019111903342328100_B6","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL [abstract]","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111903342328100_B7","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2016.34.15_suppl.3009","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory CLL [abstract]","volume":"34","author":"Porter","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111903342328100_B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.221.221","article-title":"Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL) [abstract]","volume":"128","author":"Grupp","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111903342328100_B9","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"6","key":"2019111903342328100_B10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"9967","key":"2019111903342328100_B11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"2019111903342328100_B12","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111903342328100_B13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111903342328100_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.684.684","article-title":"Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia [abstract]","volume":"128","author":"Lee","year":"2015","journal-title":"Blood"},{"issue":"303","key":"2019111903342328100_B15","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"21","key":"2019111903342328100_B16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1982.1982","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL [abstract]","volume":"124","author":"Porter","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111903342328100_B17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2009.09.007","article-title":"\u201cMIATA\u201d-minimal information about T cell assays","volume":"31","author":"Janetzki","year":"2009","journal-title":"Immunity"},{"issue":"95","key":"2019111903342328100_B18","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"8","key":"2019111903342328100_B19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"2019111903342328100_B20","author":"National Comprehensive Cancer Network Guidelines","year":"2016"},{"key":"2019111903342328100_B21","author":"National Comprehensive Cancer Network Guidelines","year":"2017"},{"key":"2019111903342328100_B22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.7150\/jca.2.331","article-title":"Chimeric antigen receptor therapy for B-cell malignancies","volume":"2","author":"Porter","year":"2011","journal-title":"J Cancer"},{"issue":"16","key":"2019111903342328100_B23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903342328100_B24","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V81.8.2093.2093","article-title":"A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS","volume":"81","author":"Ho","year":"1993","journal-title":"Blood"},{"issue":"2","key":"2019111903342328100_B25","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111903342328100_B26","first-page":"999","article-title":"In vivo traffic of indium-111-oxine labeled human lymphocytes collected by automated apheresis","volume":"31","author":"Read","year":"1990","journal-title":"J Nucl Med"},{"issue":"23","key":"2019111903342328100_B27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3769.3769","article-title":"Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS\/combined relapsed\/refractory ALL [abstract]","volume":"126","author":"Rheingold","year":"2015","journal-title":"Blood"},{"issue":"224","key":"2019111903342328100_B28","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"2019111903342328100_B29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"22","key":"2019111903342328100_B30","first-page":"217","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL [abstract]","volume":"128","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111903342328100_B31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2019111903342328100_B32","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B-cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2019111903342328100_B33","author":"Schuster","year":"2017"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/21\/2317\/1403776\/blood786129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/21\/2317\/1403776\/blood786129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T08:34:37Z","timestamp":1574152477000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/21\/2317\/36672\/Cellular-kinetics-of-CTL019-in-relapsedrefractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,11,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-06-786129","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,23]]}}}